S

Satellos Bioscience Inc
XTSX:MSCL

Watchlist Manager
Satellos Bioscience Inc
XTSX:MSCL
Watchlist
Price: 0.56 CAD 1.82%
Market Cap: 56.2m CAD

Satellos Bioscience Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Satellos Bioscience Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
S
Satellos Bioscience Inc
XTSX:MSCL
EPS (Diluted)
CA$0
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
EPS (Diluted)
$0
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
-5%
Repare Therapeutics Inc
NASDAQ:RPTX
EPS (Diluted)
-$1
CAGR 3-Years
-43%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
EPS (Diluted)
-$3
CAGR 3-Years
-31%
CAGR 5-Years
-38%
CAGR 10-Years
-38%
Spectral Medical Inc
TSX:EDT
EPS (Diluted)
CA$0
CAGR 3-Years
-55%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
No Stocks Found

Satellos Bioscience Inc
Glance View

Market Cap
56.2m CAD
Industry
Biotechnology

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).

MSCL Intrinsic Value
Not Available
S

See Also

What is Satellos Bioscience Inc's EPS (Diluted)?
EPS (Diluted)
-0.3 CAD

Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's EPS (Diluted) amounts to -0.3 CAD.

What is Satellos Bioscience Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-2%

Over the last year, the EPS (Diluted) growth was 50%.

Back to Top